What is F2G?
F2G operates at the intersection of innovative science and patient-centric healthcare, focusing exclusively on the development of novel therapies for life-threatening fungal pathogens. By prioritizing the creation of effective antifungal treatments, the company addresses a significant unmet medical need in the global healthcare landscape. Its market position is defined by a tenacious commitment to research and development, supported by a robust network of institutional backers who specialize in the life sciences sector. As the company matures, it continues to leverage its scientific expertise to advance a portfolio of therapeutic candidates designed to combat the growing threat of resistant fungal infections.
How much funding has F2G raised?
F2G has raised a total of $347.9M across 8 funding rounds:
Series A
$6.1M
Private Equity
$9.2M
Other Financing Round
$11.8M
Private Equity
$30M
Series C
$60M
Series D
$60.8M
Unspecified
$70M
Other Financing Round
$100M
Series A (2002): $6.1M, investors not publicly disclosed
Private Equity (2008): $9.2M, investors not publicly disclosed
Other Financing Round (2008): $11.8M supported by BankInvest Biomedical Venture, K Nominees, Merifin Capital, and Astellas Venture Management
Private Equity (2012): $30M featuring Novartis BioVenture Fund, Merifin Capital, Astellas Venture Management, Advent Life Sciences, and Sunstone Capital
Series C (2016): $60M backed by Novartis Venture Fund, Aisling Capital, Novo A/S, Brace Pharma Capital, Merifin Capital, Advent Life Sciences, Sectoral Asset Management, and Sunstone Capital
Series D (2020): $60.8M with participation from Brace Pharma Capital, Novo Holdings, Advent Life Sciences, Morningside Ventures, and Cowen Healthcare Investments
Unspecified (2022): $70M led by Advent Life Sciences, Sofinnova Partners, Morningside Venture Capital, Forbion, Cowen Healthcare Investments, and Novo Holdings
Other Financing Round (2024): $100M supported by Sofinnova Partners, The AMR Action Fund, Advent Life Sciences, ICG, and Novo Holdings
Key Investors in F2G
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, established in 1999 and headquartered in Hellerup, Denmark.
Advent Life Sciences
Advent Life Sciences is a leading trans-Atlantic venture capital firm focused on building innovative life sciences businesses in the UK, Europe, and the USA.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
What's next for F2G?
With the recent capital injection, F2G is well-positioned to accelerate its clinical programs and expand its therapeutic reach. The strategic focus will likely remain on navigating the complexities of late-stage drug development and regulatory approval processes. By maintaining its focus on high-impact, first-in-class medicines, the company is poised to strengthen its competitive advantage in the biopharmaceutical market. Future growth will be driven by the continued validation of its proprietary science and the potential for commercializing treatments that offer superior outcomes for vulnerable patient populations facing limited therapeutic alternatives.
See full F2G company page
